BioAge Labs full-year collaboration revenue beats estimates

BioAge Labs

24/03/2026 13:09

Overview

US biopharmaceutical firm posts full-year collaboration revenue, beating analyst expectations

Net loss for 2025 widened as R&D and G&A expenses increased

Company completed $132.3 mln upsized follow-on public offering to fund operations through 2029

Outlook

Company expects existing cash to fund operations through 2029

Result Drivers

COLLABORATION REVENUE - First-time collaboration revenue driven by Novartis research agreement initiated in 2025

HIGHER R&D SPENDING - Increased R&D expenses due to expanded activities for BGE-102, Novartis collaboration, and APJ agonist programs

INCREASED G&A EXPENSES - Higher G&A costs mainly from increased personnel expenses, legal fees, and insurance

Company press release: ID:nGNX9GGXd4

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Collaboration Revenue
Beat
$9 mln
$7.11 mln (7 Analysts)
FY EPS
-$2.24
FY Net Income
-$80.61 mln
FY Income from Operations
-$92.78 mln
FY Operating Expenses
$101.78 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for BIOAGE Labs Inc is $52.00, about 179.1% above its March 23 closing price of $18.63

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)